Skip to Content

Generic Elestrin Availability

Elestrin is a brand name of estradiol, approved by the FDA in the following formulation(s):

ELESTRIN (estradiol - gel, metered;transdermal)

  • Manufacturer: MEDA PHARMS
    Approval date: December 15, 2006
    Strength(s): 0.06% (0.87GM/ACTIVATION) [RLD]

Has a generic version of Elestrin been approved?

No. There is currently no therapeutically equivalent version of Elestrin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elestrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Formulations for transdermal or transmucosal application
    Patent 7,198,801
    Issued: April 3, 2007
    Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
    Assignee(s): Antares Pharma IPL AG
    The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
    Patent expiration dates:
    • June 25, 2022
      ✓ 
      Drug product
  • Formulations for transdermal or transmucosal application
    Patent 7,470,433
    Issued: December 30, 2008
    Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
    Assignee(s): Antares Pharma IPL AG
    The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
    Patent expiration dates:
    • August 3, 2021
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide